title: Safety and Efficacy of Combivent Respimat in Chronic Obstructive Pulmonary Disease (COPD)

summary: The primary objective of this study is to compare the effect of ipratropium bromide/salbutamol inhalation spray combination administered by the Respimat® inhaler (20 mcg/100 mcg), ipratropium bromide inhalation spray administered by the Respimat® inhaler (20 mcg), and COMBIVENT® MDI administered q.i.d on FEV1 at intervals over a treatment period of 12 weeks in patients with COPD. Specifically, non-inferiority of Combivent Respimat® to COMBIVENT® MDI in FEV1 AUC from 0 to 6 hours , superiority of Combivent Respimat® to Atrovent Respimat® monotherapy in FEV1 AUC from 0 to 4 hours, and non-inferiority of Combivent Respimat® to Atrovent Respimat® monotherapy in FEV1 AUC from 4 to 6 hours will be analyzed. In addition, steady state pharmacokinetics over one dosing interval following 4 weeks of therapy will be characterized in a subgroup of patients.

ReferenceCitation: Zuwallack R, De Salvo MC, Kaelin T, Bateman ED, Park CS, Abrahams R, Fakih F, Sachs P, Pudi K, Zhao Y, Wood CC; Combivent Respimat Inhaler Study Group. Efficacy and safety of ipratropium bromide/albuterol delivered via Respimat inhaler versus MDI. Respir Med. 2010 Aug;104(8):1179-88. doi: 10.1016/j.rmed.2010.01.017. Epub 2010 Feb 20.

lead_sponsor: Boehringer Ingelheim

location_country:
Poland
New Zealand
United Kingdom
Argentina
United States
Korea, Republic of
Greece
South Africa
Turkey
Taiwan
Ukraine
Russian Federation
France

location_facility: 1012.56.07007 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.01029 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.44008 The Staploe Medical Centre

location_facility: 1012.56.30001 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.01069 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.01085 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.30011 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.01003 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.01054 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.01073 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.3304A Centre Médical Erdre Saint Augustin

location_facility: 1012.56.01018 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.48010 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.88605 Taichung Veterans General Hospital

location_facility: 1012.56.90002 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.01033 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.01080 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.01002 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.01034 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.30007 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.82009 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.88604 Chang Gong Memorial Hospital

location_facility: 1012.56.38004 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.01017 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.82001 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.01013 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.88602 Taipei Veterans General Hospital

location_facility: 1012.56.01065 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.44006 Colchester General Hospital

location_facility: 1012.56.48003 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.01008 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.48001 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.54015 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.01064 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.01023 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.01079 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.01088 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.01044 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.01010 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.48005 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.01049 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.07001 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.01070 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.82008 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.01072 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.64001 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.48011 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.01006 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.01019 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.48007 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.01066 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.01038 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.01067 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.01009 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.01005 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.82007 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.01083 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.54006 CENTRO PRIVADO de MEDICINA RESPIRATORIA

location_facility: 1012.56.44002 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.01021 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.01074 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.01075 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.07002 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.90006 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.38006 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.01056 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.64003 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.01053 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.07009 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.01015 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.54007 CLINICA PRIVADA de MONTE GRANDE

location_facility: 1012.56.82006 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.44009 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.27006 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.27008 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.88601 Chang Gung Memorial Hosp-Linkou

location_facility: 1012.56.30010 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.82005 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.01020 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.01058 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.07010 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.30002 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.01030 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.01028 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.01022 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.54001 Centro Médico de la Dra. De Salvo

location_facility: 1012.56.01027 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.01024 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.01032 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.01078 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.07003 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.27002 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.01076 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.64006 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.01025 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.54011 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.44007 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.48002 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.01036 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.48009 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.01063 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.01045 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.54013 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.01081 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.27004 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.01057 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.01001 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.01026 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.01060 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.54005 Instituto de Diagnóstico Cardiovascular La Plata

location_facility: 1012.56.54009 Instituto de Investigaciones Clínicas

location_facility: 1012.56.90001 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.01062 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.30009 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.38005 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.01043 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.54014 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.01031 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.01011 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.01052 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.3305A Centre hospitalier Germon & Gauthier

location_facility: 1012.56.30003 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.01035 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.01093 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.27005 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.01007 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.01004 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.01016 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.01077 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.01050 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.44003 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.54008 HOSPITAL ITALIANO de ROSARIO

location_facility: 1012.56.44010 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.38002 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.01014 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.90005 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.27001 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.01090 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.27009 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.01012 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.54002 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.01068 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.01039 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.07005 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.82010 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.82002 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.01089 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.48006 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.27003 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.38001 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.30013 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.01084 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.90003 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.01047 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.01055 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.30014 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.01051 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.01037 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.01059 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.48004 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.01071 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.54012 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.64004 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.64005 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.01087 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.01048 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.88603 National Taiwan University Hospital

location_facility: 1012.56.01040 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.01042 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.01082 Boehringer Ingelheim Investigational Site

location_facility: 1012.56.07008 Boehringer Ingelheim Investigational Site


title: A 2-Year, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study To Evaluate The Long-Term Efficacy And Safety Of CP-945,598 In The Treatment Of Obese Subjects

summary: The purpose of this study is to examine the long-term weight loss and safety of CP-945,598 in obese adults

status: Terminated

study_completion_date_type: Actual

study_type: Interventional

design_allocation: Randomized

primary_purpose: Treatment

enrollment_type: Actual

lead_sponsor: Pfizer

location_country:
Germany
United Kingdom
Argentina
Australia
Sweden
Mexico
United States
Korea, Republic of
Spain
Chile
France

intervention_type: Drug

lead_sponsor_type: industriel

status_simplified: Unknown


title: Randomized, Multicenter, Double-blinded, Phase IV Study Evaluating the Efficacy (as Measured by Sustained Virological Response) and Safety of 360 μg Induction Dosing of Pegasys® in Combination With Higher Copegus® Doses in Treatment-naïve Patients With Chronic Hepatitis C Genotype 1 Virus Infection of High Viral Titer and Baseline Body Weight Greater Than or Equal to 85 kg

summary: This 4-arm study will compare the efficacy and safety of PEGASYS induction and maintenance dosing, versus standard fixed dosing in combination with Copegus, and the efficacy and safety of higher dose versus standard dose Copegus in combination with PEGASYS. Patients with chronic hepatitis C (CHC) genotype 1 infection of high viral titer, and baseline body weight ≥85 kg, will be randomized to one of 4 groups, to receive one of the following: a) PEGASYS 180 µg subcutaneously (sc) weekly plus Copegus 1200 mg orally (po) daily; b) PEGASYS 180 µg sc weekly plus Copegus 1400-1600 mg po daily; c)PEGASYS 360 µg sc weekly (induction) followed by 180 µg sc weekly (maintenance) plus Copegus 1200 mg po daily; or d) PEGASYS 360 µg sc weekly (induction) followed by 180 µg sc weekly (maintenance) plus Copegus 1400-1600 mg po daily. Following 48 weeks treatment, there will be a 24-week period of treatment-free follow-up. The anticipated time on study treatment is 3-12 months, and the target sample size is 500+ individuals.

status: Completed

ReferenceType: derived

ReferenceCitation: Reddy KR, Shiffman ML, Rodriguez-Torres M, Cheinquer H, Abdurakhmanov D, Bakulin I, Morozov V, Silva GF, Geyvandova N, Stanciu C, Rabbia M, McKenna M, Thommes JA, Harrison SA; PROGRESS Study Investigators. Induction pegylated interferon alfa-2a and high dose ribavirin do not increase SVR in heavy patients with HCV genotype 1 and high viral loads. Gastroenterology. 2010 Dec;139(6):1972-83. doi: 10.1053/j.gastro.2010.08.051. Epub 2010 Sep 30.

lead_sponsor: Hoffmann-La Roche

location_country:
Germany
Poland
Hungary
United Kingdom
Denmark
Romania
Brazil
Netherlands
Sweden
Belgium
United States
Canada
Puerto Rico
Russian Federation
France

status_simplified: Completed


type: EudraCT Number

type: Other Identifier

title: Multicenter Study to Investigate the Bleeding Profile and the Insertion Easiness in Women Inserted With a Second Consecutive MIRENA for Contraception or Menorrhagia

summary: The purpose of this study is to assess the bleeding pattern during the last 3 months of the first MIRENA® and the first year of the second MIRENA® use.

design_allocation: Non-Randomized

ReferenceType: result

ReferenceCitation: Heikinheimo O, Inki P, Kunz M, Parmhed S, Anttila AM, Olsson SE, Hurskainen R, Gemzell-Danielsson K. Double-blind, randomized, placebo-controlled study on the effect of misoprostol on ease of consecutive insertion of the levonorgestrel-releasing intrauterine system. Contraception. 2010 Jun;81(6):481-6. doi: 10.1016/j.contraception.2010.01.020. Epub 2010 Mar 1. Erratum In: Contraception. 2023 Mar;119:109926.

ReferenceCitation: Gemzell-Danielsson K, Inki P, Boubli L, O'Flynn M, Kunz M, Heikinheimo O. Bleeding pattern and safety of consecutive use of the levonorgestrel-releasing intrauterine system (LNG-IUS)--a multicentre prospective study. Hum Reprod. 2010 Feb;25(2):354-9. doi: 10.1093/humrep/dep426. Epub 2009 Dec 1.

ReferenceCitation: Heikinheimo O, Inki P, Kunz M, Gemzell-Danielsson K. Predictors of bleeding and user satisfaction during consecutive use of the levonorgestrel-releasing intrauterine system. Hum Reprod. 2010 Jun;25(6):1423-7. doi: 10.1093/humrep/deq079. Epub 2010 Apr 8.

ReferenceCitation: Heikinheimo O, Inki P, Schmelter T, Gemzell-Danielsson K. Bleeding pattern and user satisfaction in second consecutive levonorgestrel-releasing intrauterine system users: results of a prospective 5-year study. Hum Reprod. 2014 Jun;29(6):1182-8. doi: 10.1093/humrep/deu063. Epub 2014 Mar 28.

oa_colors: green hybrid

oa_host_type: publisher;repository

evidence: open (via page says license)

host_type: publisher

license: cc-by-nc

license_normalized: cc-by-nc

version: publishedVersion

evidence: oa repository (via OAI-PMH doi match)

host_type: repository

repository_institution: PubMed Central - Europe PMC

repository_normalized: PubMed Central

evidence: oa repository (via pmcid lookup)

license_normalized: no license

evidence: oa repository (semantic scholar lookup)

version: submittedVersion

repositories_concat: PubMed Central;pdfs.semanticscholar.org

unpaywall_oa_status: hybrid

publisher_dissemination: Oxford University Press

lead_sponsor: Bayer

location_country: Finland Ireland Sweden France


title: Effects of Bosentan on Morbidity and Mortality in Patients With Idiopathic Pulmonary Fibrosis - a Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Group Sequential, Phase III Study.

acronym: BUILD 3

summary: BUILD 3 is a prospective, multicenter, randomized, double-blind, parallel group, placebo-controlled, event-driven, group sequential, phase III superiority study. The primary objective is to demonstrate that bosentan delays disease worsening or death in patients with Idiopathic Pulmonary Fibrosis.

ReferenceCitation: King TE Jr, Brown KK, Raghu G, du Bois RM, Lynch DA, Martinez F, Valeyre D, Leconte I, Morganti A, Roux S, Behr J. BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011 Jul 1;184(1):92-9. doi: 10.1164/rccm.201011-1874OC. Epub 2011 Apr 7.

lead_sponsor: Actelion

location_country:
Germany
Ireland
Australia
Japan
Croatia
Canada
Serbia
France
Czech Republic
Switzerland
United States
Belgium
Italy
United Kingdom
Netherlands
Austria
Korea, Republic of
Spain
Israel

location_facility: SoonChunHyang University Bucheon Hospital

location_facility: Walter C. Mackenzie Health Sciences Centre-Univeristy of Alberta

location_facility: Prince Charles Hospital - Lung Transplant, Thoraic Dept.

location_facility: University of Virginia - Div. of Pulmonary & Critical Care

location_facility: Pulmonary and Critical Care Medicine-Stanford University Medical Center

location_facility: University Hospital Basel-Div of Pneumology

location_facility: Institut za Plucne bolesti Vojvodine, Sremska Kamenica

location_facility: National Jewish Medical & Research Center

location_facility: University Hospital Olomouc - Dept of Respiratory Disease-IP Pavlova

location_facility: Azienda Sanitaria di Forli-Presidio Ospedaliero Stabilimento

location_facility: University of Chicago - Section of Pulmonary, Dept of Medicine, Respiratory Clinical Research

location_facility: Yale University School of Medicine-Dept of Internal Med-Pulmonary & Critical Care

location_facility: Institut za Plucne bolest l TBC Klinickog Centra Srbije

location_facility: Hopital Notre Dame - Centre Hospitalier de L'Universit de Montreal

location_facility: Royal Adelaide Hospital-Respiratory Clinical Trials Unit

location_facility: Toronto General Hospital-Rosedale Medical Center PFT Lab

location_facility: Institut de Cardiologie et de Pneumologie de l'Universite Laval

location_facility: Medizinische Universitätsklinik, Abteilung Pneumologie

location_facility: UCLA-Division of Pulmonary & Critical Care

location_facility: University Hospital for Lung Disease "Jordanovac"

location_facility: Klinik Löwenstein GmbH-Medizinische Klinik 1 Pneumologie-Kardiologie

location_facility: Rambam Medical Centre-Div. for Pulmonary Disease

location_facility: University of Pennsylvania Medical Center

location_facility: Highland Hospital - Pulmonary Department

location_facility: St. Luke's Medical Group, Cardio-Pulmonary Research

location_facility: Medizinische Universität Graz-Klinische Abteilung für Pulmonologie

location_facility: Azienda Ospedaliero-Universitaria San Luigi Gonzaga

location_facility: Inselspital Bern-Div of Pulmonary Medicine

location_facility: Azienda Ospedaliera di Padova - Immunologia Clinica

location_facility: The Health Care Corporation of St. John's-Eastern Health

location_facility: Klinikum der Universität München Medizinische Klinik und Poliklinik 1 - Grosshadern

location_facility: Ospedale San Giuseppe Milanocuore, Unita Operativa di Pneumologia

location_facility: Klinik Donaustauf-Zentrum für Pneumologie

location_facility: University degli Studi Siena, Policlinico le Scotte

location_facility: Medical University of Vienna and AKH-Div of Pulmonology

location_facility: Justus-Liebig-Universitat Giessen-Zentrum für Innere Medizin

location_facility: Thomayer Faculty Hospital Prague-Dept of Respiratory Disease

location_facility: University of Texas-Southwestern Dallas-Div. of Pulm & Critical Care Unit

location_facility: University Hopital Zurich-Clinic for Pneumology & Lung Transplant Program

location_facility: St. Vincent's Public Hospital, Lung Transplantation & Respiratory Medicine

location_facility: Pulmonary Istitute-Rabin Medical Centre: Beilinson Campus

location_facility: Kanagawa Cardiovascular Respiratory Center

location_facility: Hadassah Medical Organization: Ein Karem-Institute of Pulmonology

location_facility: Hospital Clinic Barcelona (Pneumology Service)

location_facility: Fachkrankenhaus Coswig; Centre for Pulmonology and Thoracic Surgery

location_facility: Tel-Aviv Sourasky Medical Centre-Institute of Pulmonary & Allergic Diseases

location_facility: Medical University of Innsbruck-Div. of Clinical & Internal Medicine

location_facility: Royal Perth Hospital; Advanced Lung Disease Unit


title: A Six Month, Open-Label Outpatient, Randomized Parallel Group Trial Assessing The Impact Of Dry Powder Inhaled Insulin (Exubera®) On Glycemic Control Compared To Insulin Glargine (Lantus®) In Patients With Type 2 Diabetes Mellitus Who Are Poorly Controlled On A Combination Of Two Or More Oral Agents

summary: To compare efficacy and safety of Exubera® vs Lantus® in patients with type 2 diabetes mellitus.

location_country: Finland Germany Poland Norway Sweden Netherlands Switzerland Belgium Spain France


type: U.S. NIH Grant/Contract

title: A Randomized Trial of Unruptured Brain Arteriovenous Malformations

acronym: ARUBA

summary: The purpose of this study is to determine if medical management is better than invasive therapy for improving the long-term outcome of patients with unruptured brain arteriovenous malformations.

ReferenceType: background

ReferenceCitation: Stapf C, Mohr JP, Choi JH, Hartmann A, Mast H. Invasive treatment of unruptured brain arteriovenous malformations is experimental therapy. Curr Opin Neurol. 2006 Feb;19(1):63-8. doi: 10.1097/01.wco.0000200546.14668.78.

ReferenceCitation: Mohr JP, Overbey JR, Hartmann A, Kummer RV, Al-Shahi Salman R, Kim H, van der Worp HB, Parides MK, Stefani MA, Houdart E, Libman R, Pile-Spellman J, Harkness K, Cordonnier C, Moquete E, Biondi A, Klijn CJM, Stapf C, Moskowitz AJ; ARUBA co-investigators. Medical management with interventional therapy versus medical management alone for unruptured brain arteriovenous malformations (ARUBA): final follow-up of a multicentre, non-blinded, randomised controlled trial. Lancet Neurol. 2020 Jul;19(7):573-581. doi: 10.1016/S1474-4422(20)30181-2.

oa_host_type: repository

repository_institution: University of Groningen / Centre for Information Technology - University of Groningen research database

repository_institution: University of Edinburgh - Edinburgh Research Explorer

version: acceptedVersion

unpaywall_oa_status: green

publisher_dissemination: Elsevier

ReferenceCitation: Mohr JP, Overbey JR, von Kummer R, Stefani MA, Libman R, Stapf C, Parides MK, Pile-Spellman J, Moquete E, Moy CS, Vicaut E, Moskowitz AJ, Harkness K, Cordonnier C, Biondi A, Houdart E, Berkefeld J, Klijn CJM, Barreau X, Kim H, Hartmann A; International ARUBA Investigators. Functional impairments for outcomes in a randomized trial of unruptured brain AVMs. Neurology. 2017 Oct 3;89(14):1499-1506. doi: 10.1212/WNL.0000000000004532. Epub 2017 Sep 6.

evidence: oa repository (via OAI-PMH title and first author match)

repository_institution: California Digital Library - eScholarship

repositories_concat: PubMed Central;escholarship.org

repositories_institution: California Digital Library - eScholarship

publisher_dissemination: Wolters Kluwer Health

ReferenceCitation: Mohr JP, Parides MK, Stapf C, Moquete E, Moy CS, Overbey JR, Al-Shahi Salman R, Vicaut E, Young WL, Houdart E, Cordonnier C, Stefani MA, Hartmann A, von Kummer R, Biondi A, Berkefeld J, Klijn CJ, Harkness K, Libman R, Barreau X, Moskowitz AJ; international ARUBA investigators. Medical management with or without interventional therapy for unruptured brain arteriovenous malformations (ARUBA): a multicentre, non-blinded, randomised trial. Lancet. 2014 Feb 15;383(9917):614-21. doi: 10.1016/S0140-6736(13)62302-8. Epub 2013 Nov 20.

repositories_concat: PubMed Central

ReferenceCitation: Stapf C. The rationale behind "A Randomized Trial of Unruptured Brain AVMs" (ARUBA). Acta Neurochir Suppl. 2010;107:83-5. doi: 10.1007/978-3-211-99373-6_13.

ReferenceCitation: Stapf C, Mohr JP. Unruptured brain arteriovenous malformations should be treated conservatively: yes. Stroke. 2007 Dec;38(12):3308-9. doi: 10.1161/STROKEAHA.107.504605. Epub 2007 Oct 25. No abstract available.

lead_sponsor: Columbia University

collaborators: National Institute of Neurological Disorders and Stroke (NINDS)

location_country:
Finland
Germany
Italy
United Kingdom
Australia
Brazil
Netherlands
Austria
Switzerland
United States
Korea, Republic of
Spain
Canada
France

location_facility: Hôpital Sainte Anne, Service de Neurochirurgie, Centre Hospitalier Sainte Anne, 1, Rue Cabanis

location_facility: New York Presbyterian Hospital, Columbia Campus, Neurological Institute, 710 W. 168th St

location_facility: Frenchay Hospital, Neuroradiology Department

location_facility: Austin Health, University of Melbourne 300 Waterdale Rd,Heidelberg Heights

location_facility: Hôpital de la Cavale-Blanche, Service de Neurologie, Bd. Tanguy Pringent

location_facility: Kaiser Permanente Los Angeles Medical Center,4867 Sunset Blvd

location_facility: Centre Hospitalier Régional et Universitaire de Lille, Clinique de Neurochirurgie, Hopital Roger Salengro, CHRU

location_facility: Loyola University Stritch School of Medicine, Department of Neurology, 2160 S 1st Ave, Bldg 105/2700

location_facility: Department of Neurosurgery, Universitair Medisch Centrum Groningen Hanzeplein 1

location_facility: Department of Neurosurgery, Newcastle General Hospital, Westgate Road

location_facility: Bellaria Hospital, Department of Neurosurgery

location_facility: Utrecht University Hospital, Heidelberglaan 100, 3584 CX

location_facility: Western General Hospital, Bramwell Dott Building, Department of Clinical Neurosciences, Crewe Road

location_facility: European Coordinating Center: Dept. of Neurology, Hôpital Lariboisière, 2 Rue Ambroise Paré, 75475 Paris cedex 10,

location_facility: Institute of Neurology, Box 6, The National Hospital, Queen Square

location_facility: Universitätsklinikum Essen, Institut für Diagnostische und Interventionelle Radiologie und Neuroradiologie, Hufelandstraße 55

location_facility: Hamilton General Hospital .237 Barton Street East

location_facility: Barrow Neurological Institute, 350 West Thomas Road

location_facility: Rudolfstiftung, Neurochirurgie, Juchgasse 25, A-1030

location_facility: Uniklinikum Frankfurt, Institut für Neuroradiologie, Schleusenweg 2-16

location_facility: Servizio di Neuroradiologia, Ospedale San Raffaele, Via Olgettina 60

location_facility: John P. Murtha Neuroscience & Pain Institute,1450 Scapl Ave, Suite 120,

location_facility: Michigan Head and Spine Institute, Providence Hospital and Medical Center, 16001 West Nine Mile Road

location_facility: University of Iowa Hospitals, Department of Neurology, 200 Hawkins Drive ,

location_facility: Hospital Universitari de Bellvitge, Sección de Neuroradiologia, c/ Feixa Llarga s/n, L'Hospitalet de Llobregat

location_facility: CHUM Notre Dame Hospital, Department of Radiology, 1560 Sherbrooke Street

location_facility: CHU Henri Mondor, Service de Neuroradiologie

location_facility: Uniklinikum Dresden, Neuroradiologie, Fetscherstr. 74

location_facility: Hôpital Lariboisière, Service de Neuroradiologie, 2, Rue Ambroise Paré

location_facility: Klinikum Großhadern, LMU München, Neurologische Klinik und Poliklinik, Marchionistr. 15

location_facility: University of Texas Medical School in Houston

location_facility: Uniklinik Freiburg, Neuroradiology-Neurocenter, Breisacher Str. 64

location_facility: Universitätsklinik Heidelberg, Department of Neurosurgery, Im Neuenheimer Feld 400

location_facility: Department of Neurology, Royal Hallamshire Hospital, Glossop Road

location_facility: Brackenridge Hospital, Brain and Spine Center, 601 East 15th Street

location_facility: SUNY Downstate Medical Center, 451 Clarkson Avenue, Box 1189

location_facility: Thomas Jefferson Hospital for Neuroscience

location_facility: Berufsgenossenschaftliche Kliniken Bergmannstrost, Klinik für Neurochirurgie, Merseburger Str. 165

location_facility: Walton Centre for Neurology, Lower Lane Fazakerley

location_facility: Universitätsklinik für Neurologie, Anichstrasse 35, 6020 Innsbruck

location_facility: University of Virginia School of Medicine, Department of Neurosurgery, P.O. Box 800212

location_facility: Charité Campus Benjamin Franklin (CCBF), Neurologische Klinik, Hindenburgdamm 30

location_facility: Department of Neuroradiology, University Medical Center Hamburg-Eppendorf, Martinistrasse 52

location_facility: Consultant Neurologist, Department of Neurology, Leeds General Infirmary, Great George Street

location_facility: Inselspital, Neurologische Klinik, 3010 Bern

location_facility: Mount Sinai Hospital, One Gustave L. Levy Place, Department of Neurosurgery- Box 1136

location_facility: Helsinki University Central Hospital, Dept. of Neurosurgery, Topeliuksenkatu 5, Helsinki, P.O. Box 266

location_facility: University of California at San Francisco, 1001 Potrero Avenue- Rm 3C-38

location_facility: University of California at Los Angeles, UCLA School of Medicine, 710 Westwood Plaza

location_facility: Neuroscience Department, Royal Preston Hospital, Sharoe Green Lane, Fulwood

intervention_type: Procedure

lead_sponsor_type: academique


title: A Prospective, Randomized, Active Controlled, Parallel Group, Multi-center Trial to Assess the Efficacy and Safety of Mycophenolate Mofetil (MMF) in Inducing Response and Maintaining Remission in Subjects With Lupus Nephritis.

summary: This 2 arm study assessed the efficacy of Mycophenolate Mofetil (MMF; CellCept) compared to cyclophosphamide in inducing a response in patients with lupus nephritis, and the long term efficacy of MMF compared to azathioprine in maintaining remission and renal function. Patients were randomized to receive either MMF (1.5 g twice daily [bid]) or cyclophosphamide (0.5-1.0 g/m^2 in monthly pulses) in the induction phase. Those patients meeting criteria for response were re-randomized for entry into the maintenance phase, to receive either MMF (1 g bid) or azathioprine (2 mg/kg/day).

ReferenceCitation: Sundel R, Solomons N, Lisk L; Aspreva Lupus Management Study (ALMS) Group. Efficacy of mycophenolate mofetil in adolescent patients with lupus nephritis: evidence from a two-phase, prospective randomized trial. Lupus. 2012 Nov;21(13):1433-43. doi: 10.1177/0961203312458466. Epub 2012 Aug 24.

ReferenceCitation: Dooley MA, Jayne D, Ginzler EM, Isenberg D, Olsen NJ, Wofsy D, Eitner F, Appel GB, Contreras G, Lisk L, Solomons N; ALMS Group. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med. 2011 Nov 17;365(20):1886-95. doi: 10.1056/NEJMoa1014460.

ReferenceCitation: Dall'Era M, Stone D, Levesque V, Cisternas M, Wofsy D. Identification of biomarkers that predict response to treatment of lupus nephritis with mycophenolate mofetil or pulse cyclophosphamide. Arthritis Care Res (Hoboken). 2011 Mar;63(3):351-7. doi: 10.1002/acr.20397. Epub 2010 Nov 15.

ReferenceCitation: Ginzler EM, Wofsy D, Isenberg D, Gordon C, Lisk L, Dooley MA; ALMS Group. Nonrenal disease activity following mycophenolate mofetil or intravenous cyclophosphamide as induction treatment for lupus nephritis: findings in a multicenter, prospective, randomized, open-label, parallel-group clinical trial. Arthritis Rheum. 2010 Jan;62(1):211-21. doi: 10.1002/art.25052. Erratum In: Arthritis Rheum. 2010 Oct;62(10):3005.

ReferenceCitation: Isenberg D, Appel GB, Contreras G, Dooley MA, Ginzler EM, Jayne D, Sanchez-Guerrero J, Wofsy D, Yu X, Solomons N. Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study. Rheumatology (Oxford). 2010 Jan;49(1):128-40. doi: 10.1093/rheumatology/kep346. Epub 2009 Nov 20.

sponsor_collaborators:
Hoffmann-La Roche
Aspreva Pharmaceuticals

location_country:
France
Germany
Italy
Portugal
Hungary
Argentina
United Kingdom
Australia
Brazil
Mexico
Belgium
United States
China
Spain
Greece
Canada
Czech Republic


title: A Phase II, Multicenter, Randomized, Open-label, Active Controlled Study to Evaluate the Safety and Efficacy of Micafungin Salvage Mono-therapy Versus Active Control Intravenous Salvage Mono-therapy in Patients With Invasive Aspergillosis

summary: To evaluate the efficacy and safety of micafungin in patients with proven invasive aspergillosis and who are refractory or intolerant to previous systemic antifungal therapy. To compare the efficacy and safety of the micafungin therapy with the active control arm

lead_sponsor: Astellas Pharma Inc

location_country:
France
Germany
Italy
Colombia
Poland
Hungary
Argentina
Brazil
Belgium
Spain
Croatia
Czech Republic


title: A Phase III, International, Randomised, Double Blind, Parallel-Group Study to Assess the Efficacy of Zactima™ Versus Tarceva® in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Failure of at Least One Prior Chemotherapy

summary: To determine if ZD6474 a new investigational drug, is effective in treating Non Small Lung Cancer and if so, how it compares with another type of anti cancer therapy chemotherapy, Erlotinib

ReferenceCitation: Natale RB, Thongprasert S, Greco FA, Thomas M, Tsai CM, Sunpaweravong P, Ferry D, Mulatero C, Whorf R, Thompson J, Barlesi F, Langmuir P, Gogov S, Rowbottom JA, Goss GD. Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol. 2011 Mar 10;29(8):1059-66. doi: 10.1200/JCO.2010.28.5981. Epub 2011 Jan 31.

ReferenceCitation: Platt A, Morten J, Ji Q, Elvin P, Womack C, Su X, Donald E, Gray N, Read J, Bigley G, Blockley L, Cresswell C, Dale A, Davies A, Zhang T, Fan S, Fu H, Gladwin A, Harrod G, Stevens J, Williams V, Ye Q, Zheng L, de Boer R, Herbst RS, Lee JS, Vasselli J. A retrospective analysis of RET translocation, gene copy number gain and expression in NSCLC patients treated with vandetanib in four randomized Phase III studies. BMC Cancer. 2015 Mar 23;15:171. doi: 10.1186/s12885-015-1146-8.

oa_colors: green gold

evidence: oa journal (via doaj)

license: cc-by

license_normalized: cc-by

unpaywall_oa_status: gold

publisher_dissemination: Springer-Nature

lead_sponsor: Genzyme, a Sanofi Company

location_country:
Germany
Argentina
Australia
Brazil
Thailand
Canada
France
Hong Kong
Denmark
United States
Indonesia
India
China
Philippines
Italy
Norway
United Kingdom
Netherlands
Mexico
Korea, Republic of
Spain
Taiwan


title: An Open Label, Stratified, Single-arm Phase II Study of Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumor (NET) After Failure of Cytotoxic Chemotherapy

summary: The purpose of this study was to assess the efficacy and safety of everolimus in the treatment of advanced pancreatic neuroendocrine tumor (NET) not responsive to cytotoxic chemotherapy. All patients were treated with everolimus until either tumor progression was documented using a standard criteria that measures tumor size called Response Evaluation Criteria in Solid tumors (RECIST), or until unacceptable toxicity occurred, or until the patient or investigator requested discontinuation of treatment.

lead_sponsor: Novartis Pharmaceuticals

location_country:
Germany
Italy
Argentina
Australia
Sweden
Netherlands
Belgium
United States
Spain
Canada
France

location_facility: University of Wisconsin Hospital & Clinics

location_facility: University of Iowa Hospitals and Clinics

location_facility: Cedars-Sinai Outpatient Cancer Center/Samuel Oschin Comprehensive Cancer Inst.

location_facility: H. Lee Moffit Cancer Center & Research Institute

location_facility: Arthur G. James Cancer Hospital/Ohio State University


title: A Three Cohort Phase II Trial of BMS-275183 Given Orally on a Twice Weekly Schedule in Pretreated Locally Advanced or Metastatic NSCLC Patients

summary:
BMS-275183 given orally twice weekly to patients pretreated for locally advanced or metastatic NSCLC will show anti-tumor activity in any of the 3 separate cohorts of the patients enrolled:

Cohort I: Patients previously treated with one taxane containing regimen.
Cohort II: Patients previously treated with a platinum based but non-taxane containing regimen.
Cohort III: Patients previously treated with both a chemotherapy regimen and one EGFR-TKI (epidermal growth factor receptor-tyrosine kinase inhibitor) compound.

Patients in cohorts I and II should have not been treated with a prior EGFR-TKI compound. Prior treatment with a VEGFR (vascular endothelial growth factor receptor) inhibitor compound is allowed for all the patients provided that the VEGFR inhibitor is not also an EGFR inhibitor.

lead_sponsor: Bristol-Myers Squibb

location_country:
Italy
United Kingdom
Netherlands
Belgium
United States
Spain
Canada
France


title: A 12-month Double-blind, Randomized, Multicenter, Active-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg and 1.25 mg Fingolimod (FTY720) Administered Orally Once Daily Versus Interferon ß-1a (Avonex) Administered im Once Weekly in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase

acronym: TRANSFORMS

summary: This study assessed the safety, tolerability, and efficacy of 2 doses of oral fingolimod versus interferon β-1a to reduce the frequency of relapses in patients with relapsing-remitting multiple sclerosis.

ReferenceCitation: Cohen JA, Khatri B, Barkhof F, Comi G, Hartung HP, Montalban X, Pelletier J, Stites T, Ritter S, von Rosenstiel P, Tomic D, Kappos L; TRANSFORMS (TRial Assessing injectable interferoN vS. FTY720 Oral in RRMS) Study Group. Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study. J Neurol Neurosurg Psychiatry. 2016 May;87(5):468-75. doi: 10.1136/jnnp-2015-310597. Epub 2015 Jun 25.

repository_institution: Le Centre pour la Communication Scientifique Directe - HAL - Aix-Marseille Université

repository_normalized: HAL

repositories:
HAL
PubMed Central

repositories_concat: HAL;PubMed Central

publisher_dissemination: British Medical Journal

ReferenceCitation: Khatri BO, Pelletier J, Kappos L, Hartung HP, Comi G, Barkhof F, von Rosenstiel P, Meng X, Grinspan A, Hashmonay R, Cohen JA; TRANSFORMS Study Group. Effect of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod vs. interferon beta-1a intramuscular: Subgroup analyses of the Trial Assessing Injectable Interferon vs. Fingolimod Oral in Relapsing-Remitting Multiple Sclerosis (TRANSFORMS). Mult Scler Relat Disord. 2014 May;3(3):355-63. doi: 10.1016/j.msard.2013.11.006. Epub 2013 Dec 12.

oa_host_type: closed

repositories_concat: closed

ReferenceCitation: Chinea Martinez AR, Correale J, Coyle PK, Meng X, Tenenbaum N. Efficacy and safety of fingolimod in Hispanic patients with multiple sclerosis: pooled clinical trial analyses. Adv Ther. 2014 Oct;31(10):1072-81. doi: 10.1007/s12325-014-0154-4. Epub 2014 Sep 23.

publisher_dissemination: Springer

ReferenceCitation: Zarbin MA, Jampol LM, Jager RD, Reder AT, Francis G, Collins W, Tang D, Zhang X. Ophthalmic evaluations in clinical studies of fingolimod (FTY720) in multiple sclerosis. Ophthalmology. 2013 Jul;120(7):1432-9. doi: 10.1016/j.ophtha.2012.12.040. Epub 2013 Mar 24.

ReferenceCitation: Khatri B, Barkhof F, Comi G, Hartung HP, Kappos L, Montalban X, Pelletier J, Stites T, Wu S, Holdbrook F, Zhang-Auberson L, Francis G, Cohen JA; TRANSFORMS Study Group. Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. Lancet Neurol. 2011 Jun;10(6):520-9. doi: 10.1016/S1474-4422(11)70099-0. Epub 2011 May 13.

ReferenceCitation: Twiss J, Doward LC, McKenna SP, Eckert B. Interpreting scores on multiple sclerosis-specific patient reported outcome measures (the PRIMUS and U-FIS). Health Qual Life Outcomes. 2010 Oct 11;8:117. doi: 10.1186/1477-7525-8-117.

ReferenceCitation: Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, Pelletier J, Capra R, Gallo P, Izquierdo G, Tiel-Wilck K, de Vera A, Jin J, Stites T, Wu S, Aradhye S, Kappos L; TRANSFORMS Study Group. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010 Feb 4;362(5):402-15. doi: 10.1056/NEJMoa0907839. Epub 2010 Jan 20.

lead_sponsor: Novartis

location_country:
Germany
Italy
Portugal
Hungary
Argentina
United Kingdom
Australia
Brazil
Switzerland
Austria
Belgium
United States
Korea, Republic of
Spain
Greece
Canada
Egypt
France

location_facility: Axiom Clinical Research of Florida, 2919 Swann Avenue, Suite 401

location_facility: General Hospital of Athens G. Gennimatas, 154 Mesogeion Ave.

location_facility: Landesklinikum St. Poelten, Probst-Ruehrer-Str. 4

location_facility: University of Miami, Department of Neurology

location_facility: Osp. Clinicizzato Colle dell'Ara - Università G. D'Annunzio

location_facility: The Neurology Center, 3907 Waring Road, Suite 3

location_facility: Associated Neurologists, PC, 69 Sand Pit Road, Suite 300

location_facility: Unitat de Neuroimmunologia Clinica, Hospital Vall d'Hebron

location_facility: Al Azhar University, 11 Talaat Harb St, Fourth Floor, Apt 18

location_facility: Centre Hospitalier de Poissy, 10 rue du Champ Gaillard

location_facility: Irmandade da Santa Casa de Misericordia de Porto Alegre

location_facility: North Central Neurology Associates, PC, 1809 Kress Street

location_facility: Yale University Multiple Sclerosis Center

location_facility: Ciutat Sanitaria I, Universitaria De Bellvitge, c/o Feixa Llarga, Hospitalet de Llobregat

location_facility: Azienda Ospedaliera Careggi - Università degli Studi

location_facility: Debreceni Egyetem Orvos es Egszstd. Centr.

location_facility: Centre Hospitalier Universitaire de Sherbrooke, 3001 12th Avenue North

location_facility: Pecsi Tudomanyegyetem Neurologiai Klinika

location_facility: Universitätsspital Basel, Neurochirugishen Poliklinik

location_facility: Neurology Associates, PA, 301 N. Maitland Avenue, Suite A1

location_facility: Policlinico - Università degli Studi Federico II

location_facility: The Walton Centre for Neurology and Neurosurgery

location_facility: Azienda Ospedaliera Sant'Andrea - Università La Sapienza

location_facility: Box Hill Hopsital, Level 3, 16 Arnold Street

location_facility: Errikos Dinan General Hospital, 107 Mesogion Ave.

location_facility: Hopital La Timone Cpcet, Rue Jean Moulin

location_facility: Ahepa University General Hospital of Thessaloniki, 1 Stilp. Kyriakidi Str.

location_facility: Integra Clinical Research, 4242 Medical Drive, Suite 6100

location_facility: Hoppital Pasteur, Archet II, 30 avenue de la Voie

location_facility: Hopital Central, 29 Avenue du Marechal de Lattre de Tassigny

location_facility: West Virginia University Health Associates

location_facility: Azienda Ospedaliera di Padova - Università degli Studi

location_facility: Liverpool Hospital, Neurology Department, Health Services Building, 4th Floor, Goulburn and Campbell Street

location_facility: Az. Osp. Ospedale S. Martino - Università degli Studi

location_facility: Mid America Neuroscience Institute, 8550 Marshall Drive, Suite 100

location_facility: University of Pittsburgh, Department of Neurology

location_facility: Az. Osp. Universitaria Policlinico Tor Vergata

location_facility: The Ottawa General Hospital, 501 Smyth Rd.

location_facility: University Physician Group, #1 Barnes-Jewish Hospital Plaza, Suite 16304

location_facility: Metropolitan Hospital, Ethnarchou Makariou 6 & Eleftheriou Venizelou 1

location_facility: St. Michael's Hospital, Chief, Division of Neurology, 30 Bond Street,Suite 3007 - Shuter Wing

location_facility: General University Hospital of Patra-RIO

location_facility: Fundacion Rosarina de Neurorehabilitacion

location_facility: Osp. Magg. Pol. Mangiagalli e Regina Elena - Fond. IRCCS

location_facility: Yonsei Univ. Med. Center,Severance Hospital, 134 Shinchon-dong, Suedaemoon-ku

location_facility: Center for Neurological Disorders - Aurora St. Luke's Med Center

location_facility: Mountain Empire Neurological Associates, PC, 3183 West State Street, Suite 1201

location_facility: Absher Neurology, 274-A Commonwealth Drive

location_facility: Fraser Health MS Clinic, Burnaby Hospital, 3935 Kincaid Street

location_facility: Raleigh Neurology Associates, 1540 Sunday Drive

location_facility: Landes-Nervenklinik Christian Doppler Klinik

location_facility: Montreal Neurological Institute, 3801 University Street

location_facility: Private Clinic, 7 Batal Ahmed Abdelaziz St Abdeen

location_facility: Istituto di Scienze Neurologiche Università di Catania

location_facility: Neurology & Neuroscience Associates, Inc

location_facility: Az. Osp. Ospedale Consorziale e Policlinico

location_facility: Ospedali Riuniti Umberto I - GM Lancisi - G.Salesi

location_facility: Associated Neurologists of Southern CT, PC, 75 Kings Highway Cutoff

location_facility: Universitätsklinik f. Neurologie Innsbruck

location_facility: University of South Florida, Department of Neurology

location_facility: University of Florida Health Science Center

location_facility: Nationaal Multiple Sclerose Centrum v.z.w

location_facility: Nepean Medical Centre, 1 Centrepointe Drive, Suite 407

location_facility: Regionaal Ziekenhuis Sint-Trudo - Campus Sint-Jozef

location_facility: Azienda Ospedaliera Universitaria Arcispedale Sant'Anna

location_facility: National Cancer Center, 809 Madu 1-dong, Ilsan-gu


title: A Randomised, Double-Blind, Double-Dummy, Parallel Group Comparison of 24 Weeks of Treatment With Ropinirole Immediate Release Tablets (REQUIP IR) or Ropinirole Prolonged Release Tablets (SK&F-101468) in Advanced Stage Parkinson's Disease Subjects Who Are Not Adequately Controlled on L-dopa.

summary: This study was designed to compare the effectiveness and tolerability of a new prolonged release formulation of ropinirole with the currently marketed immediate release formulation which is prescribed in many countries. The new prolonged release formulation allows the drug to be taken once a day rather than three times a day. This study will also evaluate the side effects of the new prolonged release formulation of ropinirole

study_start_date_type: Actual

lead_sponsor: GlaxoSmithKline

location_country:
Germany
Italy
Poland
Hungary
United Kingdom
Romania
Spain
South Africa
Czechia
Ukraine
Bulgaria
Canada
Russian Federation
France


title: A Randomized, Open-label Study Comparing the Effects of Olanzapine Pamoate Depot With Oral Olanzapine on Treatment Outcomes in Outpatients With Schizophrenia

summary: To compare the health outcome of patients with schizophrenia, who are at risk for relapse, when treated with a long acting injection form of olanzapine versus treatment with oral olanzapine.

ReferenceCitation: Atkins S, Detke HC, McDonnell DP, Case MG, Wang S. A pooled analysis of injection site-related adverse events in patients with schizophrenia treated with olanzapine long-acting injection. BMC Psychiatry. 2014 Jan 14;14:7. doi: 10.1186/1471-244X-14-7.

ReferenceCitation: Peuskens J, Porsdal V, Pecenak J, Handest P, D'yachkova Y, Brousil R, Deberdt W. Schizophrenia symptoms and functioning in patients receiving long-term treatment with olanzapine long-acting injection formulation: a pooled analysis. BMC Psychiatry. 2012 Aug 31;12:130. doi: 10.1186/1471-244X-12-130.

ReferenceCitation: McDonnell DP, Detke HC, Bergstrom RF, Kothare P, Johnson J, Stickelmeyer M, Sanchez-Felix MV, Sorsaburu S, Mitchell MI. Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, II: investigations of mechanism. BMC Psychiatry. 2010 Jun 10;10:45. doi: 10.1186/1471-244X-10-45.

ReferenceCitation: Detke HC, McDonnell DP, Brunner E, Zhao F, Sorsaburu S, Stefaniak VJ, Corya SA. Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, I: analysis of cases. BMC Psychiatry. 2010 Jun 10;10:43. doi: 10.1186/1471-244X-10-43.

lead_sponsor: Eli Lilly and Company

location_country:
Portugal
Slovakia
Argentina
Romania
Brazil
United States
Spain
Greece
Taiwan
Canada
Puerto Rico
France

location_facility: For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.


acronym: CLASSIC I

summary:
Clofarabine (injection) is approved by the Food and Drug Administration (FDA) for the treatment of pediatric patients 1 to 21 years old with relapsed acute or refractory lymphoblastic leukemia (ALL) who have had at least 2 prior treatment regimens.

There is no recommended standard treatment for relapsed or refractory acute myelogenous leukemia in older patients. Cytarabine is the most commonly used drug to treat these patients. This study will determine if there is benefit by combining clofarabine with cytarabine. Patients will be randomized to receive up to 3 cycles of treatment with either placebo in combination with cytarabine or clofarabine in combination with cytarabine. Randomization was stratified by remission status following the first induction regimen (no remission [i.e., CR1 = refractory] or remission <6 months vs CR1 = remission ≥6 months). CR1 is defined as remission after first pre-study induction regimen. The safety and tolerability of clofarabine in combination with cytarabine and cytarabine alone will be monitored throughout the study.

ReferenceCitation: Clofarabine + Ara-c improves response rates and event-free survival, not overall survival, in older patients with relapsed/refractory AML compared to Ara-c alone: Updated CLASSIC I study results. H.M. Kantarjian, M. Wetzler, D. Rizzieri, G. J. Schiller, M. H. Jagasia, R. K. Stuart, S. Ganguly, D. Avigan, M. Craig, R. Collins, M. B. Maris, T. Kovacsovics, S. Goldberg, K. Seiter, P. Hari, J. Greiner, N. Vey, C. Recher, F. Ravandi, E.S. Wang, S. Eckert, D. Huebner and S. Faderl. Haematologica - 16th Congress of EHA Abstracts. 2011; 96(S2): 196.

ReferenceCitation: Clofarabine plus cytarabine compared to cytarabine alone in older patients with relapsed or refractory (R/R) acute myelogenous leukemia (AML): Results from the phase III CLASSIC 1 trial. S. Faderl, M. Wetzler, D. Rizzieri, G. J. Schiller, M. H. Jagasia, R. K. Stuart, S. Ganguly, D. Avigan, M. Craig, R. Collins, M. B. Maris, T. Kovacsovics, S. Goldberg, K. Seiter, P. Hari, F. Ravandi, E. S. Wang, S. Eckert, D. Huebner, and H. Kantarjian JCO - ASCO Meeting Abstracts. 2011; 29:6503.

ReferenceCitation: Faderl S, Wetzler M, Rizzieri D, Schiller G, Jagasia M, Stuart R, Ganguly S, Avigan D, Craig M, Collins R, Maris M, Kovacsovics T, Goldberg S, Seiter K, Hari P, Greiner J, Vey N, Recher C, Ravandi F, Wang ES, Vasconcelles M, Huebner D, Kantarjian HM. Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I Trial. J Clin Oncol. 2012 Jul 10;30(20):2492-9. doi: 10.1200/JCO.2011.37.9743. Epub 2012 May 14.

ReferenceCitation: Ganguly S, Kantarjian HM, Wetzler M, Rizzieri D, Schiller G, Jagasia M, et al. Subsequent hematopoietic stem cell transplantation (HSCT) associated with longer survival in patients with relapsed/refractory (R/R) acute myelogenous leukemia (AML) after Clo+Ara-C or Ara-C alone: a landmark analysis from the CLASSIC I trial. Biol Blood Marrow Transplant 2012;18(2Suppl):S211-S212.

ReferenceCitation: Ganguly S, Kantarjian HM, Wetzler M, Rizzieri D, Schiller G, Jagasia M, et al. Subsequent HSCT in the CLASSIC I Study Associated with Longer Survival in Patients With Relapsed/Refractory AML After Clo+Ara-C Or Ara-C Alone: A Landmark Analysis. Haematologica - 17th Congress of EHA Abstracts. 2012; 97(s1):32

location_facility: University of Utah - Huntsman Cancer Institute

location_facility: Medizinische Hochschule Hannover, Zentrum fur Innere Medizin, Abt. Haematologie / Onkologie

location_facility: Medizinische Klinik der Technischen, Universität München

location_facility: UT Southwestern Medical Center, Simmons Comprehensive Cancer Center

location_facility: University of Southern California, Kenneth Norris Cancer Center

location_facility: The Cancer Center at Hackensack University Medical Center

location_facility: University of Texas Health Sciences Center

location_facility: University of Colorado Health Science Center

location_facility: Azienda Ospedaliera "Antonio Cardarelli"

location_facility: West Virginia University Hospitals, Mary Babb Randolph Cancer Center

location_facility: University of Oklahoma Health Sciences Center

location_facility: Louisiana State University Health Science Center

location_facility: University of Kentucky, Markey Cancer Center

location_facility: University of Arkansas for Medical Sciences, Arkansas Cancer Research Center

location_facility: Wake Forest University School of Medicine

title: A Phase III Randomized, Double-blind, Controlled Study Comparing Clofarabine and Cytarabine Versus Cytarabine Alone in Adult Patients 55 Years and Older With Acute Myelogenous Leukemia (AML) Who Have Relapsed or Are Refractory After Receiving up to Two Prior Induction Regimens

source: euctr

location_country:
Germany
Italy
United States
Canada
France


title: An Open-Label Phase III Study to Assess the Long Term Safety Profile of GW433908 Containing Regimens in HIV-1 Infected Subjects

summary: GW433908 (fosamprenavir; FPV)is a pro-drug of amprenavir (APV) which is more water soluble and can be formulated into a tablet with a reduced pill burden (four 700mg tablets of FPV versus sixteen 150mg capsules daily for APV. This study is designed to provide additional information on long term safety and tolerability of FPV containing regimens for those subjects who received FPV in previous GlaxoSmithKline studies.

lead_sponsor: ViiV Healthcare

sponsor_collaborators:
ViiV Healthcare
GlaxoSmithKline

location_country:
Italy
Portugal
United Kingdom
Brazil
United States
Spain
Chile
France


title: Phase III Trial of Combined Immunochemotherapy With Fludarabine, Cyclophosphamide and Rituximab (FCR) Versus Chemotherapy With Fludarabine and Cyclophosphamide (FC) Alone in Patients With Previously Untreated Chronic Lymphocytic Leukaemia

summary: This randomized phase III trial is studying fludarabine, cyclophosphamide, and rituximab to see how well they work compared to fludarabine and cyclophosphamide in treating patients with B-cell chronic lymphocytic leukemia.

ReferenceCitation: Bloehdorn J, Krzykalla J, Holzmann K, Gerhardinger A, Jebaraj BMC, Bahlo J, Humphrey K, Tausch E, Robrecht S, Mertens D, Schneider C, Fischer K, Hallek M, Dohner H, Benner A, Stilgenbauer S. Integrative prognostic models predict long-term survival after immunochemotherapy in chronic lymphocytic leukemia patients. Haematologica. 2022 Mar 1;107(3):615-624. doi: 10.3324/haematol.2020.251561.

license: publisher-specific license

license_normalized: publisher-specific

publisher_dissemination: Ferrata Storti Foundation (Haematologica)

ReferenceCitation: Jaramillo S, Agathangelidis A, Schneider C, Bahlo J, Robrecht S, Tausch E, Bloehdorn J, Hoechstetter M, Fischer K, Eichhorst B, Goede V, Hallek M, Dohner H, Rosenquist R, Ghia P, Stamatopoulos K, Stilgenbauer S. Prognostic impact of prevalent chronic lymphocytic leukemia stereotyped subsets: analysis within prospective clinical trials of the German CLL Study Group (GCLLSG). Haematologica. 2020 Nov 1;105(11):2598-2607. doi: 10.3324/haematol.2019.231027.

ReferenceCitation: Kreuzberger N, Damen JA, Trivella M, Estcourt LJ, Aldin A, Umlauff L, Vazquez-Montes MD, Wolff R, Moons KG, Monsef I, Foroutan F, Kreuzer KA, Skoetz N. Prognostic models for newly-diagnosed chronic lymphocytic leukaemia in adults: a systematic review and meta-analysis. Cochrane Database Syst Rev. 2020 Jul 31;7(7):CD012022. doi: 10.1002/14651858.CD012022.pub2.

repository_institution: University of Oxford - Oxford University Research Archive (ORA)

repositories_concat: PubMed Central;ora.ox.ac.uk

publisher_dissemination: Wiley

ReferenceCitation: Dimier N, Delmar P, Ward C, Morariu-Zamfir R, Fingerle-Rowson G, Bahlo J, Fischer K, Eichhorst B, Goede V, van Dongen JJM, Ritgen M, Bottcher S, Langerak AW, Kneba M, Hallek M. A model for predicting effect of treatment on progression-free survival using MRD as a surrogate end point in CLL. Blood. 2018 Mar 1;131(9):955-962. doi: 10.1182/blood-2017-06-792333. Epub 2017 Dec 18.

oa_colors: green other

evidence: open (via free article)

repository_institution: DANS - Data Archiving and Networked Services - NARCIS - National Academic Research and Collaborations Information System

repository_institution: Erasmus University Rotterdam - EUR Research Repository

unpaywall_oa_status: bronze

publisher_dissemination: American Society of Hematology

ReferenceCitation: Fischer K, Bahlo J, Fink AM, Goede V, Herling CD, Cramer P, Langerbeins P, von Tresckow J, Engelke A, Maurer C, Kovacs G, Herling M, Tausch E, Kreuzer KA, Eichhorst B, Bottcher S, Seymour JF, Ghia P, Marlton P, Kneba M, Wendtner CM, Dohner H, Stilgenbauer S, Hallek M. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. Blood. 2016 Jan 14;127(2):208-15. doi: 10.1182/blood-2015-06-651125. Epub 2015 Oct 20.

oa_host_type: publisher

ReferenceCitation: Weisser M, Yeh RF, Duchateau-Nguyen G, Palermo G, Nguyen TQ, Shi X, Stinson SY, Yu N, Dufour A, Robak T, Salogub GN, Dmoszynska A, Solal-Celigny P, Warzocha K, Loscertales J, Catalano J, Larratt L, Rossiev VA, Bence-Bruckler I, Geisler CH, Montillo M, Fischer K, Fink AM, Hallek M, Bloehdorn J, Busch R, Benner A, Dohner H, Valente N, Wenger MK, Stilgenbauer S, Dornan D. PTK2 expression and immunochemotherapy outcome in chronic lymphocytic leukemia. Blood. 2014 Jul 17;124(3):420-5. doi: 10.1182/blood-2013-12-538975. Epub 2014 Jun 10.

evidence: open (via free pdf)

ReferenceCitation: Pflug N, Bahlo J, Shanafelt TD, Eichhorst BF, Bergmann MA, Elter T, Bauer K, Malchau G, Rabe KG, Stilgenbauer S, Dohner H, Jager U, Eckart MJ, Hopfinger G, Busch R, Fink AM, Wendtner CM, Fischer K, Kay NE, Hallek M. Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia. Blood. 2014 Jul 3;124(1):49-62. doi: 10.1182/blood-2014-02-556399. Epub 2014 May 5.

ReferenceCitation: Stilgenbauer S, Schnaiter A, Paschka P, Zenz T, Rossi M, Dohner K, Buhler A, Bottcher S, Ritgen M, Kneba M, Winkler D, Tausch E, Hoth P, Edelmann J, Mertens D, Bullinger L, Bergmann M, Kless S, Mack S, Jager U, Patten N, Wu L, Wenger MK, Fingerle-Rowson G, Lichter P, Cazzola M, Wendtner CM, Fink AM, Fischer K, Busch R, Hallek M, Dohner H. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. Blood. 2014 May 22;123(21):3247-54. doi: 10.1182/blood-2014-01-546150. Epub 2014 Mar 20.

ReferenceCitation: Eichhorst BF, Fischer K, Fink AM, Elter T, Wendtner CM, Goede V, Bergmann M, Stilgenbauer S, Hopfinger G, Ritgen M, Bahlo J, Busch R, Hallek M; German CLL Study Group (GCLLSG). Limited clinical relevance of imaging techniques in the follow-up of patients with advanced chronic lymphocytic leukemia: results of a meta-analysis. Blood. 2011 Feb 10;117(6):1817-21. doi: 10.1182/blood-2010-04-282228. Epub 2010 Dec 7.

ReferenceCitation: Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J, Hensel M, Hopfinger G, Hess G, von Grunhagen U, Bergmann M, Catalano J, Zinzani PL, Caligaris-Cappio F, Seymour JF, Berrebi A, Jager U, Cazin B, Trneny M, Westermann A, Wendtner CM, Eichhorst BF, Staib P, Buhler A, Winkler D, Zenz T, Bottcher S, Ritgen M, Mendila M, Kneba M, Dohner H, Stilgenbauer S; International Group of Investigators; German Chronic Lymphocytic Leukaemia Study Group. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010 Oct 2;376(9747):1164-74. doi: 10.1016/S0140-6736(10)61381-5.

sponsor_collaborators:
Hoffmann-La Roche
German CLL Study Group

location_country:
France
Germany
Italy
New Zealand
Israel
Denmark
Australia
Austria
Belgium
Spain
Czech Republic

location_facility: Marseille Institute of Cancer - Institut J. Paoli and I. Calmettes

location_facility: Internistische Gemeinschaftspraxis - Berlin

location_facility: Allg. Krankenhaus der Stadt Wien Universitaets-Kinderklinik

location_facility: Gemeinschaftspraxis Fuer Innere Medizin, Hematologie Und Onkologie

location_facility: Klinikum der Universitaet Muenchen - Grosshadern Campus

location_facility: Internistische Gemeinschaftspraxis - Stuttgart

location_facility: Charite - Universitaetsmedizin Berlin - Campus Benjamin Franklin

location_facility: Staedtisches Krankenhaus Muenchen - Harlaching

location_facility: St. Marien-Hospital Hamm - Klinik Knappenstrasse

location_facility: Hamatologie/Onkologie Praxisgemeinschaft - Muenchen

location_facility: Onkologische Gemeinschaftspraxis - Dresden

location_facility: Hospital General Universitario Morales Meseguer

location_facility: Medizinische Klinik und Poliklinik II - Universitaetsklinikum Wuerzburg

location_facility: Onkologische Schwerpunktpraxis Dr. Schmidt

location_facility: Fondazione Centro San Raffaele Del Monte Tabor

location_facility: Klinik fuer Onkologie - Katharinenhospital Stuttgart

location_facility: Internistische Gemeinschaftspraxis - Kassel

location_facility: Krankenanstalt Mutterhaus der Borromaerinnen

location_facility: Gemeinschaftspraxis Fuer Innere Medizin, Haematologie Und Internistische Onkologie

location_facility: Krankenhaus Barmherzige Brueder Regensburg

location_facility: Schwerpunktpraxis Hamatologie/Onkologie - Wesel

location_facility: Staedtische Kliniken Frankfurt am Main - Hoechst

location_facility: Medizinische Universitaetsklinik I at the University of Cologne

location_facility: Klinik Fuer Innere Medizin, Hematology/Oncology, Ernst Moritz Armdt Universitaet

location_facility: Praxis Fuer Haematologie Internistische Onkologie

location_facility: Internistische Gemeinschaftspraxis - Oldenburg

location_facility: Onkologische Schwerpunktpraxis at Facharzt fuer Innere Medizin

location_facility: Universitaetsklinkum Magdeburg der Otto-von-Guericke-Universitaet Magdeburg

location_facility: Comprehensive Cancer Center Ulm at Universitaetsklinikum Ulm

location_facility: Klinik und Poliklinik fuer Innere Medizin - Universitaet Rostock

location_facility: Praxis fuer Haematologie und Interne Onkologie

location_facility: Internistische Gemeinschaftspraxis - Offenbach

location_facility: Krankenhaus Siloah - Medizinische Klinik II

location_facility: Haematologisch - Onkologische Gemeinschaftspraxis

location_facility: Copenhagen County Herlev University Hospital

location_facility: First Medical Clinic of Charles University Hospital

location_facility: Clinic for Bone Marrow Transplantation and Hematology and Oncology

location_facility: Privatklinik Dr. R. Schindlbeck GmbH & Co. KG

location_facility: Hamatologisch - Onkologische Praxis Wurzburg

location_facility: Internistische Gemeinschaftspraxis - Forchheim

location_facility: Policlinico A. Gemelli - Universita Cattolica del Sacro Cuore

location_facility: Internistische Gemeinschaftspraxis - Magdeburg

location_facility: Hamatologische/Onkologische Gemeinschaftspraxis - Augsburg

location_facility: University Hospital Schleswig-Holstein - Kiel Campus

location_facility: University Hospital in Pilsen - Lochotin

location_facility: Internistische Onkologische Praxis - Kronach

location_facility: University Medical Center Hamburg - Eppendorf

location_facility: Praxis Fur Hamatologie und Onkologie Ahaus

location_facility: Riverview Cancer Care Medical Associates, PC

location_facility: Staedtisches Klinikum Magdeburg - Altstadt

location_facility: Marienhospital at Ruhr University Bochum

location_facility: Klinikum Rechts Der Isar - Technische Universitaet Muenchen

location_facility: Stiftungsklinikum Mittelrhein - Gesundheitszentrum Evangelisches Stift Sankt Martin Koblenz gGmbH

location_facility: Centre Hospitalier Universitaire de Rennes

location_facility: Westmead Institute for Cancer Research at Westmead Hospital

location_facility: Praxis Fuer Internistische Haematologie / Onkologie

location_facility: Onkologische Gemeinschaftspraxis - Trier

location_facility: St. Marien Hospital - Katholisches Krankenhaus Hagen gGmbH


title: A One Year Double-blind Trial to Investigate the Efficacy and Safety of Meloxicam Oral Suspension 0.25mg/kg and 0.125 mg/kg Administered Once Daily in Comparison to Naproxen Oral Suspension 5mg/kg Administered Twice Daily in Children With Juvenile Rheumatoid Arthritis.

summary: A one year double-blind trial to investigate the efficacy and safety of meloxicam oral suspension 0.25 mg/kg and 0.125 mg/kg administered once daily in comparison to naproxen oral suspension 5 mg/kg administered twice daily in children with Juvenile Rheumatoid Arthritis.

location_country:
Germany
Italy
United Kingdom
Austria
Belgium
Russian Federation
France

location_facility: Univ.-Klinik für Kinder- und Jugendheilkunde Wien

location_facility: Medical Faculty of Russian People Friendship University

location_facility: Gottfried Preyersches Kinderspital d. Stadt Wien

location_facility: Scientific Research Institute of Pediatric Hematology

location_facility: Boehringer Ingelheim Investigational Site


title: Double-blind, Randomized, Dose Optimization Trial of Three Doses of Tipranavir Boosted With Low Dose Ritonavir (TPV/RTV) in Multiple Antiretroviral Drug-experienced Subjects

summary: A dose defining study of the protease inhibitor tipranavir (TPV), boosted with low dose ritonavir (RTV). Three dose combinations of TPV/RTV are administered to multiple antiretroviral experienced patients and the dose that achieves the best efficacy and safety as determined by evaluation of 2, 8, and 24-week virologic response and adverse event and laboratory profile measures would be selected for further clinical study.

location_country:
Germany
Italy
United Kingdom
Australia
Netherlands
United States
Spain
Canada
France

location_facility: Wake Forest University Baptist Medical Center

location_facility: Fondazione Centro S. Raffaele del Monte Tabor

location_facility: 4th Floor Research Office (St Stephens Centre)

location_facility: Hospital Clínico y Provincial de Barcelona - HIV

location_facility: Community Research Initiative of New England

location_facility: Montreal Chest Institute - McGill University Health Centre

location_facility: Rush-Presbytarian-St Luke's Medical Center


title: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Alvimopan 0.5mg Once Daily and 0.5mg Twice Daily for 12 Weeks for the Treatment of Opioid-Induced Bowel Dysfunction in Adults Taking Opioid Therapy for Persistent Non-Cancer Pain

summary: Adults who are taking opioid therapy for persistent non-cancer pain and have resulting opioid-induced bowel dysfunction (OBD) will be randomized (1:1:1) to one of 2 alvimopan arms, or to placebo. The primary objective of this phase 3 confirmatory study is to compare alvimopan with placebo for efficacy in the treatment of OBD. The primary efficacy endpoint is based on frequency of bowel movements. Subjects will be required to: (1) track their bowel movements and other bowel symptoms and (2) attend 6 clinic visits over 4 months.

ReferenceCitation: Irving G, Penzes J, Ramjattan B, Cousins M, Rauck R, Spierings EL, Kleoudis CS, Snidow JW, Pierce A, Wurzelmann J, Mortensen ER. A randomized, placebo-controlled phase 3 trial (Study SB-767905/013) of alvimopan for opioid-induced bowel dysfunction in patients with non-cancer pain. J Pain. 2011 Feb;12(2):175-84. doi: 10.1016/j.jpain.2010.06.013.

lead_sponsor: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

location_country:
New Zealand
Hungary
Norway
Australia
Sweden
Netherlands
Switzerland
United States
Spain
South Africa
Canada
France


title: Phase III Randomized, Controlled, Open-label Trial to Investigate the Antiviral Activity, Tolerability and Safety of TMC114/r in Treatment- Naive HIV-1 Infected Patients.

summary: The purpose of this study is to compare the efficacy, safety and tolerability of TMC114/r versus Kaletra (a combination pill of lopinavir and ritonavir, ("lpv/rtv") in HIV-1 infected patients who have never been treated with anti-retroviral medications (referred to as "treatment-naïve" patients).

ReferenceCitation: Mills AM, Nelson M, Jayaweera D, Ruxrungtham K, Cassetti I, Girard PM, Workman C, Dierynck I, Sekar V, Abeele CV, Lavreys L. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis. AIDS. 2009 Aug 24;23(13):1679-88. doi: 10.1097/QAD.0b013e32832d7350.

ReferenceCitation: Orkin C, DeJesus E, Khanlou H, Stoehr A, Supparatpinyo K, Lathouwers E, Lefebvre E, Opsomer M, Van de Casteele T, Tomaka F. Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naive patients in the ARTEMIS trial. HIV Med. 2013 Jan;14(1):49-59. doi: 10.1111/j.1468-1293.2012.01060.x. Epub 2012 Oct 23.

lead_sponsor: Tibotec Pharmaceuticals, Ireland

location_country:
Germany
Argentina
Australia
Costa Rica
Thailand
Chile
Canada
France
Denmark
Switzerland
United States
Belgium
Malaysia
Puerto Rico
Guatemala
United Kingdom
Singapore
Austria
Mexico
Spain
Greece
Panama
South Africa
Taiwan
Russian Federation


title: A Phase III, Multicenter, Double-blind, Randomized, Active-controlled, Parallel Group, Non-inferiority Study Comparing 150 mg Risedronate Monthly With 5 mg Risedronate Daily in the Treatment of Postmenopausal Osteoporosis (PMO)

summary: The purpose of this trial is to study the efficacy of a single-dose monthly dosing regimen as compared to the standard daily dosing regimen of risedronate 5 mg daily.

lead_sponsor: Warner Chilcott

sponsor_collaborators:
Warner Chilcott
Sanofi

location_country:
Finland
Poland
Hungary
Argentina
Norway
Australia
Brazil
Lebanon
Belgium
United States
Spain
Canada
Estonia
France


title: A Comparison of Telmisartan 80 mg + Hydrochlorothiazide 12.5 mg With Amlodipine 10 mg + Hydrochlorothiazide 12.5 mg in the Control of Blood Pressure in Older Patients With Predominantly Systolic Hypertension. A Prospective, Randomised, Open-label, Blinded End-point Evaluation. (ATHOS Study)

summary: The primary objective of this study was test non-inferiority of telmisartan 80 mg + hydrochlorothiazide (HCTZ) 12.5 mg in comparison to amlodipine 10 mg + HCTZ 12.5 mg in reducing ambulatory systolic blood pressure (SBP) in the last 6 hours of the 24-hour dosing interval (determined by ambulatory blood pressure monitoring: ABPM) in elderly patients with predominantly systolic hypertension.

lead_sponsor: Boehringer Ingelheim

location_country:
Finland
Germany
Ireland
Italy
Denmark
Netherlands
Belgium
Spain
South Africa
France

location_facility: Hämeenlinnan lääkäriasema Oy, Linnan klinikka

location_facility: Adelaide and Meath Hospitals (incorrporating NCH)

location_facility: Azienda Ospedaliera "Maggiore della Carità"


title: A Randomized, Double-Blind, Dose Ranging, Dose Comparison-Controlled Trial to Determine the Safety and Efficacy of BMS-298585 in Subjects With Type 2 Diabetes

summary: A Randomized, Double-Blind, Dose-Ranging, Dose Comparison-Controlled Trial to Determine the Safety and Efficacy of BMS-298585 in Subjects with Type 2 Diabetes

ReferenceCitation: Rubin CJ, Viraswami-Appanna K, Fiedorek FT. Efficacy and safety of muraglitazar: a double-blind, 24-week, dose-ranging study in patients with type 2 diabetes. Diab Vasc Dis Res. 2009 Jul;6(3):205-15. doi: 10.1177/1479164109336048.

location_country:
France
Italy
Poland
United Kingdom
Argentina
Australia
Brazil
Netherlands
Mexico
Sweden
United States
Spain
South Africa
Canada
Puerto Rico
Czech Republic


title: Extension of Protocol HMR1726D/2001, A Phase II Study of the Safety and Efficacy of Teriflunomide (HMR1726) in Multiple Sclerosis With Relapses

summary: The primary objective is to assess the long-term safety of teriflunomide in multiple sclerosis subjects. The secondary objective is to assess the long-term efficacy.

ReferenceCitation: Comi G, Freedman MS, Meca-Lallana JE, Vermersch P, Kim BJ, Parajeles A, Edwards KR, Gold R, Korideck H, Chavin J, Poole EM, Coyle PK. Prior treatment status: impact on the efficacy and safety of teriflunomide in multiple sclerosis. BMC Neurol. 2020 Oct 6;20(1):364. doi: 10.1186/s12883-020-01937-4.

repository_institution: University of Ottawa - uO Research

repositories_concat: PubMed Central;ruor.uottawa.ca

ReferenceCitation: Confavreux C, Li DK, Freedman MS, Truffinet P, Benzerdjeb H, Wang D, Bar-Or A, Traboulsee AL, Reiman LE, O'Connor PW; Teriflunomide Multiple Sclerosis Trial Group. Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years. Mult Scler. 2012 Sep;18(9):1278-89. doi: 10.1177/1352458512436594. Epub 2012 Feb 3.

lead_sponsor: Sanofi

location_country: Canada France

location_facility:
Investigational Site Number 27
Investigational Site Number 12
Investigational Site Number 13
Investigational Site Number 15
Investigational Site Number 16
Investigational Site Number 19
Investigational Site Number 21
Investigational Site Number 30
Investigational Site Number 28
Investigational Site Number 11
Investigational Site Number 17
Investigational Site Number 14
Investigational Site Number 10
Investigational Site Number 24
Investigational Site Number 23
Investigational Site Number 18


title: Early Versus Late Initiation of Treatment With Risperdal Consta in Subjects With Schizophrenia After an Acute Episode

summary: The primary objective of this randomized trial was to investigate whether early initiation of treatment with Risperdal Consta after an acute episode was not inferior to the routine approach (oral treatment for 12 weeks followed by treatment with Risperdal Consta). .

lead_sponsor: Janssen Pharmaceutica N.V., Belgium

location_country:
Finland
France
Slovenia
Norway
United Kingdom
Denmark
Sweden
Switzerland
Greece
Israel


title: A Prospective Multi-Centre Randomised, Double-Blind, Active Comparator-Controlled, Parallel-Groups Study Comparing the Fully Human Monoclonal Anti-TNFα Antibody Adalimumab Given Every Second Week With Methotrexate Given Weekly and the Combination of Adalimumab and Methotrexate Administered Over 2 Years in Patients With Early Rheumatoid Arthritis (PREMIER).

acronym: PREMIER

summary: The purpose of the study is to assess the safety and efficacy of adalimumab in combination with methotrexate in patients with recent onset rheumatoid arthritis (RA), and to assess the long-term safety and maintenance of efficacy after treatment with adalimumab for up to 10 years.

ReferenceCitation: Smolen J, Fleischmann R, Aletaha D, Li Y, Zhou Y, Sainsbury I, Galindo IL. Disease activity improvements with optimal discriminatory ability between treatment arms: applicability in early and established rheumatoid arthritis clinical trials. Arthritis Res Ther. 2019 Nov 10;21(1):231. doi: 10.1186/s13075-019-2005-9.

ReferenceCitation: Smolen JS, van Vollenhoven RF, Florentinus S, Chen S, Suboticki JL, Kavanaugh A. Predictors of disease activity and structural progression after treatment with adalimumab plus methotrexate or continued methotrexate monotherapy in patients with early rheumatoid arthritis and suboptimal response to methotrexate. Ann Rheum Dis. 2018 Nov;77(11):1566-1572. doi: 10.1136/annrheumdis-2018-213502. Epub 2018 Aug 3.

ReferenceCitation: Keystone EC, Breedveld FC, Kupper H, Li Y, Florentinus S, Sainsbury I. Long-term use of adalimumab as monotherapy after attainment of low disease activity with adalimumab plus methotrexate in patients with rheumatoid arthritis. RMD Open. 2018 Jun 13;4(1):e000637. doi: 10.1136/rmdopen-2017-000637. eCollection 2018.

ReferenceCitation: Keystone EC, Breedveld FC, van der Heijde D, van Vollenhoven RF, Emery P, Smolen JS, Sainsbury I, Florentinus S, Kupper H, Chen K, Kavanaugh A. Achieving comprehensive disease control in patients with early and established rheumatoid arthritis treated with adalimumab plus methotrexate versus methotrexate alone. RMD Open. 2017 Sep 26;3(2):e000445. doi: 10.1136/rmdopen-2017-000445. eCollection 2017.

ReferenceCitation: Moller B, Everts-Graber J, Florentinus S, Li Y, Kupper H, Finckh A. Low Hemoglobin and Radiographic Damage Progression in Early Rheumatoid Arthritis: Secondary Analysis From a Phase III Trial. Arthritis Care Res (Hoboken). 2018 Jun;70(6):861-868. doi: 10.1002/acr.23427. Epub 2018 Apr 25.

ReferenceCitation: Burmester GR, Landewe R, Genovese MC, Friedman AW, Pfeifer ND, Varothai NA, Lacerda AP. Adalimumab long-term safety: infections, vaccination response and pregnancy outcomes in patients with rheumatoid arthritis. Ann Rheum Dis. 2017 Feb;76(2):414-417. doi: 10.1136/annrheumdis-2016-209322. Epub 2016 Jun 23.

repository_institution: University of Oxford - Oxford Academic Notes & Queries

ReferenceCitation: Landewe R, Smolen JS, Florentinus S, Chen S, Guerette B, van der Heijde D. Existing joint erosions increase the risk of joint space narrowing independently of clinical synovitis in patients with early rheumatoid arthritis. Arthritis Res Ther. 2015 May 21;17(1):133. doi: 10.1186/s13075-015-0626-1.

ReferenceCitation: Landewe R, Ostergaard M, Keystone EC, Florentinus S, Liu S, van der Heijde D. Analysis of integrated radiographic data from two long-term, open-label extension studies of adalimumab for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2015 Feb;67(2):180-6. doi: 10.1002/acr.22426.

ReferenceCitation: Keystone EC, Haraoui B, Guerette B, Mozaffarian N, Liu S, Kavanaugh A. Clinical, functional, and radiographic implications of time to treatment response in patients with early rheumatoid arthritis: a posthoc analysis of the PREMIER study. J Rheumatol. 2014 Feb;41(2):235-43. doi: 10.3899/jrheum.121468. Epub 2013 Dec 1.

ReferenceCitation: Keystone EC, Breedveld FC, van der Heijde D, Landewe R, Florentinus S, Arulmani U, Liu S, Kupper H, Kavanaugh A. Longterm effect of delaying combination therapy with tumor necrosis factor inhibitor in patients with aggressive early rheumatoid arthritis: 10-year efficacy and safety of adalimumab from the randomized controlled PREMIER trial with open-label extension. J Rheumatol. 2014 Jan;41(1):5-14. doi: 10.3899/jrheum.130543. Epub 2013 Nov 15.

ReferenceCitation: Smolen JS, van der Heijde DM, Keystone EC, van Vollenhoven RF, Goldring MB, Guerette B, Cifaldi MA, Chen N, Liu S, Landewe RB. Association of joint space narrowing with impairment of physical function and work ability in patients with early rheumatoid arthritis: protection beyond disease control by adalimumab plus methotrexate. Ann Rheum Dis. 2013 Jul;72(7):1156-62. doi: 10.1136/annrheumdis-2012-201620. Epub 2012 Aug 22. Erratum In: Ann Rheum Dis. 2013 Aug;72(8):1432.

ReferenceCitation: Strand V, Rentz AM, Cifaldi MA, Chen N, Roy S, Revicki D. Health-related quality of life outcomes of adalimumab for patients with early rheumatoid arthritis: results from a randomized multicenter study. J Rheumatol. 2012 Jan;39(1):63-72. doi: 10.3899/jrheum.101161. Epub 2011 Nov 1.

location_country:
Finland
Germany
Ireland
Australia
Canada
France
Czech Republic
Slovakia
Denmark
Switzerland
United States
Belgium
Italy
Norway
United Kingdom
Netherlands
Austria
Spain
Sweden

location_facility:
Site Reference ID/Investigator# 750
Site Reference ID/Investigator# 2437
Site Reference ID/Investigator# 752
Site Reference ID/Investigator# 333
Site Reference ID/Investigator# 428
Site Reference ID/Investigator# 4650
Site Reference ID/Investigator# 305
Site Reference ID/Investigator# 325
Site Reference ID/Investigator# 748
Site Reference ID/Investigator# 490
Site Reference ID/Investigator# 4632
Site Ref # / Investigator 96122
Site Reference ID/Investigator# 3415
Site Reference ID/Investigator# 738
Site Reference ID/Investigator# 343
Site Reference ID/Investigator# 306
Site Reference ID/Investigator# 390
Site Reference ID/Investigator# 749
Site Ref # / Investigator 95800
Site Reference ID/Investigator# 757
Site Reference ID/Investigator# 762
Site Reference ID/Investigator# 334
Site Ref # / Investigator 95795
Site Ref # / Investigator 95875
Site Reference ID/Investigator# 328
Site Reference ID/Investigator# 4635
Site Reference ID/Investigator# 304
Site Reference ID/Investigator# 756
Site Reference ID/Investigator# 6136
Site Ref # / Investigator 98256
Site Reference ID/Investigator# 1528
Site Reference ID/Investigator# 746
Site Reference ID/Investigator# 488
Site Reference ID/Investigator# 327
Site Reference ID/Investigator# 332
Site Reference ID/Investigator# 322
Site Reference ID/Investigator# 1525
Site Reference ID/Investigator# 337
Site Reference ID/Investigator# 348
Site Reference ID/Investigator# 318
Site Reference ID/Investigator# 346
Site Reference ID/Investigator# 338
Site Ref # / Investigator 96121
Site Reference ID/Investigator# 753
Site Reference ID/Investigator# 740
Site Ref # / Investigator 95958
Site Reference ID/Investigator# 344
Site Reference ID/Investigator# 763
Site Reference ID/Investigator# 316
Site Reference ID/Investigator# 319
Site Reference ID/Investigator# 755
Site Reference ID/Investigator# 3417
Site Ref # / Investigator 95957
Site Ref # / Investigator 98199
Site Reference ID/Investigator# 4646
Site Ref # / Investigator 95960
Site Reference ID/Investigator# 429
Site Reference ID/Investigator# 737
Site Reference ID/Investigator# 315
Site Reference ID/Investigator# 2533
Site Reference ID/Investigator# 759
Site Reference ID/Investigator# 4630
Site Ref # / Investigator 96116
Site Reference ID/Investigator# 2565
Site Reference ID/Investigator# 361
Site Reference ID/Investigator# 733
Site Reference ID/Investigator# 4649
Site Ref # / Investigator 6134
Site Reference ID/Investigator# 2500
Site Reference ID/Investigator# 4633
Site Ref # / Investigator 96126
Site Ref # / Investigator 98125
Site Reference ID/Investigator# 321
Site Reference ID/Investigator# 314
Site Reference ID/Investigator# 302
Site Reference ID/Investigator# 741
Site Reference ID/Investigator# 347
Site Reference ID/Investigator# 310
Site Reference ID/Investigator# 736
Site Reference ID/Investigator# 308
Site Reference ID/Investigator# 326
Site Reference ID/Investigator# 317
Site Reference ID/Investigator# 754
Site Ref # / Investigator 95719
Site Reference ID/Investigator# 339
Site Reference ID/Investigator# 2532
Site Reference ID/Investigator# 742
Site Reference ID/Investigator# 345
Site Reference ID/Investigator# 744
Site Reference ID/Investigator# 330
Site Reference ID/Investigator# 4638
Site Reference ID/Investigator# 6135
Site Reference ID/Investigator# 760
Site Reference ID/Investigator# 303
Site Reference ID/Investigator# 311
Site Reference ID/Investigator# 6133
Site Reference ID/Investigator# 1526
Site Reference ID/Investigator# 309
Site Ref # / Investigator 98255
Site Reference ID/Investigator# 307
Site Reference ID/Investigator# 313
Site Reference ID/Investigator# 4631
Site Reference ID/Investigator# 335
Site Reference ID/Investigator# 735
Site Reference ID/Investigator# 745
Site Ref # / Investigator 95878
Site Reference ID/Investigator# 4634
Site Ref # / Investigator 95877
Site Reference ID/Investigator# 734
Site Reference ID/Investigator# 728
Site Reference ID/Investigator# 751
Site Reference ID/Investigator# 323
Site Reference ID/Investigator# 2491
Site Reference ID/Investigator# 758
Site Reference ID/Investigator# 761
Site Reference ID/Investigator# 336
Site Reference ID/Investigator# 3426
Site Reference ID/Investigator# 747
Site Reference ID/Investigator# 427
Site Ref # / Investigator 98258
Site Reference ID/Investigator# 331
Site Ref # / Investigator 96120
Site Reference ID/Investigator# 739


title: A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Comparison of One-Year Treatment of Two Doses (5mg and 10mg) of Tiotropium Inhalation Solution Delivered by the Respimat Device in Patients With Chronic Obstructive Pulmonary Disease (COPD)

summary: To evaluate the long term effects of treatment with two doses of Tiotropium delivered by the Respimat inhaler in patients with COPD.

ReferenceCitation: Singh D, Wedzicha JA, Siddiqui S, de la Hoz A, Xue W, Magnussen H, Miravitlles M, Chalmers JD, Calverley PMA. Blood eosinophils as a biomarker of future COPD exacerbation risk: pooled data from 11 clinical trials. Respir Res. 2020 Sep 17;21(1):240. doi: 10.1186/s12931-020-01482-1.

repository_institution: Imperial College London - Spiral

repository_institution: University of Dundee - Discovery Research Portal

ReferenceCitation: Hohlfeld JM, Furtwaengler A, Konen-Bergmann M, Wallenstein G, Walter B, Bateman ED. Cardiac safety of tiotropium in patients with COPD: a combined analysis of Holter-ECG data from four randomised clinical trials. Int J Clin Pract. 2015 Jan;69(1):72-80. doi: 10.1111/ijcp.12596. Epub 2014 Dec 11.

license: cc-by-nc-nd

license_normalized: cc-by-nc-nd

publisher_dissemination: Hindawi

ReferenceCitation: Hodder R, Pavia D, Lee A, Bateman E. Lack of paradoxical bronchoconstriction after administration of tiotropium via Respimat(R) Soft Mist Inhaler in COPD. Int J Chron Obstruct Pulmon Dis. 2011;6:245-51. doi: 10.2147/COPD.S16094. Epub 2011 Apr 26.

location_country:
Finland
Ireland
Italy
New Zealand
United Kingdom
Australia
Netherlands
Austria
United States
Spain
Greece
South Africa
Canada
Russian Federation
France

location_facility: Baumgartner Hohe Otto Wagner Spital Wien


title: A Phase 3, Randomized, Double-blind, Placebo Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of BMS-298585 in Combination With Glyburide Therapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control on Sulfonylurea Therapy Alone

summary: A Phase 3, Randomized, Double-blind, Placebo Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of BMS-298585 in Combination with Glyburide Therapy in Subjects with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Sulfonylurea Therapy Alone.

ReferenceCitation: Rubin CJ, De Pril V, Fiedorek FT. Coadministration of muraglitazar plus glyburide: improvement of glycaemic and lipid profiles in patients with type 2 diabetes. Diab Vasc Dis Res. 2009 Apr;6(2):120-32. doi: 10.1177/1479164109336049.

location_country:
Germany
Italy
United Kingdom
Argentina
Australia
Brazil
Netherlands
Mexico
United States
Spain
Peru
Canada
Puerto Rico
Russian Federation
France


title: A Multi-center, Three-staged With Interim Analyses, Parallel, Randomized, Double-blind, fenofibrate-and Placebo-controlled Proof of Concept and Dose-response Evaluation of the Safety, Tolerability, and Effects on Plasma High-density Lipoprotein Cholesterol (HDLc) and Triglycerides of Eight Weeks Treatment With GW501516 in Otherwise Healthy Patients With Low HDLc, Mildly to Moderately Elevated Triglycerides, and Normal Low-density Lipoprotein Cholesterol (LDLc)

summary: The purpose of this clinical research study is to compare up to 3 doses of an investigational drug GW501516 to placebo (an inactive pill that looks like GW501516) to see if it is safe, well tolerated and effective in improving (raising) low levels of "good cholesterol", high-density lipoprotein cholesterol (HDLc), as compared to placebo.

location_country: Finland Germany Lithuania Portugal Norway Denmark Sweden Netherlands Belgium Estonia France


title: Recombinant Antihemophilic Factor Manufactured and Formulated Without Added Human or Animal Proteins (rAHF-PFM): Evaluation of Immunogenicity, Efficacy, and Safety in Previously Untreated Patients With Hemophilia A

summary: The purpose of this study is to evaluate whether Antihemophilic factor, recombinant, manufactured protein-free (rAHF-PFM) is effective and safe in the treatment of hemophilia A patients who have not been treated with factor VIII (FVIII) before.

ReferenceCitation: Ewenstein B., Patrone L, Schroth P, Spotts G, Fritsch S, Pavlova B, Ehrlich H. Efficacy of antihemophilic factor (recombinant), plasma/albumin-free method (rAHF-PFM) in bleed prevention. J Thromb Haemost. 2007; 5(Suppl 2): P-S-179.

ReferenceCitation: Ewenstein B., Patrone L, Schroth P, Spotts G, Fritsch S, Pavlova B, Ehrlich H. Efficacy of antihemophilic factor (recombinant), plasma/albumin-free method (rAHF-PFM) in bleed treatment. J Thromb Haemost. 2007; 5(Suppl 2)v: P-S-180.

ReferenceCitation: Shapiro A, Gruppo R, Pabinger I, Collins PW, Hay CR, Schroth P, Casey K, Patrone L, Ehrlich H, Ewenstein BM. Integrated analysis of safety and efficacy of a plasma- and albumin-free recombinant factor VIII (rAHF-PFM) from six clinical studies in patients with hemophilia A. Expert Opin Biol Ther. 2009 Mar;9(3):273-83. doi: 10.1517/14712590902729392.

ReferenceCitation: Auerswald G, Thompson AA, Recht M, Brown D, Liesner R, Guzman-Becerra N, Dyck-Jones J, Ewenstein B, Abbuehl B. Experience of Advate rAHF-PFM in previously untreated patients and minimally treated patients with haemophilia A. Thromb Haemost. 2012 Jun;107(6):1072-82. doi: 10.1160/TH11-09-0642. Epub 2012 Apr 4.

ipd_sharing: Yes

ipd_sharing_description: Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

lead_sponsor: Baxalta now part of Shire

location_country:
Germany
Italy
United Kingdom
Sweden
Austria
United States
Spain
Canada
Puerto Rico
France

intervention_type: Biological


title: Corticosteroid Therapy of Septic Shock - Corticus. A Multi-National, Prospective, Double-Blind, Randomized, Placebo-Controlled Study

acronym: Corticus

summary: The purpose of the study is to determine whether steroids decrease 28-day mortality in patients with septic shock.

ReferenceCitation: Annane D, Briegel J, Sprung CL. Corticosteroid insufficiency in acutely ill patients. N Engl J Med. 2003 May 22;348(21):2157-9. doi: 10.1056/NEJM200305223482123. No abstract available.

ReferenceCitation: Sprung CL, Annane D, Keh D, Moreno R, Singer M, Freivogel K, Weiss YG, Benbenishty J, Kalenka A, Forst H, Laterre PF, Reinhart K, Cuthbertson BH, Payen D, Briegel J; CORTICUS Study Group. Hydrocortisone therapy for patients with septic shock. N Engl J Med. 2008 Jan 10;358(2):111-24. doi: 10.1056/NEJMoa071366.

ReferenceCitation: Polito A, Sonneville R, Guidoux C, Barrett L, Viltart O, Mattot V, Siami S, Lorin de la Grandmaison G, Chretien F, Singer M, Gray F, Annane D, Brouland JP, Sharshar T. Changes in CRH and ACTH synthesis during experimental and human septic shock. PLoS One. 2011;6(11):e25905. doi: 10.1371/journal.pone.0025905. Epub 2011 Nov 3.

lead_sponsor: Hadassah Medical Organization

collaborators: European Society of Intensive Care Medicine

location_country:
Germany
France
Italy
Portugal
United Kingdom
Netherlands
Austria
Belgium
Israel

location_facility: Universitaetsklinik fuer Innere Medizin II

location_facility: Klinikum Mannheim, University of Heidelberg

location_facility: Bloomsbury Institute of Intensive Care Medicine

location_facility: Institute for Anaesthesia and Operative Intensive Care

location_facility: Centro di Rianimazione Ospedale S.Eugenio

location_facility: Krankenhaus der Barmherzigen Schwestern Ges. mbH